In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies.

Chapters:
00:35 - Guest Introduction
01:10 - SELECT Results Overview
04:25 - Next Steps for Research
07:15 - Mechanism of Action for CV Benefit
09:00 - FLOW Trial Implications
11:25 - Impact on Access
15:00 - Future of Incretin Therapies
21:45 - Predicting the Next 5-10 Years for Semaglutide